Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

Abstract PIM and PI3K/mTOR pathways are often dysregulated in prostate cancer, and may lead to decreased survival, increased metastasis and invasion. The pathways are heavily interconnected and act on a variety of common effectors that can lead to the development of resistance to drug inhibitors. Mo...

Full description

Bibliographic Details
Main Authors: Sabina Luszczak, Benjamin S. Simpson, Urszula Stopka-Farooqui, Vignesh Krishna Sathyadevan, Lina M. Carmona Echeverria, Christopher Kumar, Helena Costa, Aiman Haider, Alex Freeman, Charles Jameson, Marzena Ratynska, Imen Ben-Salha, Ashwin Sridhar, Greg Shaw, John D. Kelly, Hayley Pye, Kathy A. Gately, Hayley C. Whitaker, Susan Heavey
Format: Article
Language:English
Published: Nature Publishing Group 2020-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-020-71263-9

Internet

https://doi.org/10.1038/s41598-020-71263-9

Similar Items